Janumet versus pioglitazone

According to results presented at the ADA 70th Scientific Sessions, type 2 diabetes patients who begin initial therapy on MSD's Janumet (sitagliptin / metformin) have significantly improved glycaemic control over 32 weeks compared to patients taking pioglitazone -  a mean reduction of 1.9% in HbA1c with Janumet compared to 1.4% with pioglitazone.

In addition, patients taking Janumet also experienced weight loss while patients taking pioglitazone experienced weight gain.  Janumet recently launched as a single tablet in the UK but is not licensed for initial therapy in the UK.